Please login to the form below

Not currently logged in
Email:
Password:

Cephalon gets green light for cancer pain drug in EU

The European Commission has granted marketing authorisation for Cephalon's cancer pain drug Effentora
The European Commission has granted marketing authorisation for Cephalon's cancer pain drug Effentora.

Effentora, a buccal tablet formulation of fentanyl, which is indicated for the treatment of breakthrough cancer pain (BTCP) can now be marketed in the 27 EU member states as well as Norway and Iceland.

Cephalon, a US-based biopharmaceutical company, is seeking to bolster its standing in the European healthcare market.

Alain Aragues, president of Cephalon Europe, said: "Cephalon continues to build its presence in Europe, the Middle East and Africa, and activities are ongoing to make Effentora available quickly in the EU member countries."

"We are committed to bring new medications to the European markets that address the needs of patients with cancer," he added.

15th April 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...

Infographics